← SynDRA
CAFICRESTAT
SynDRA canonical compound SYN0039604 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | AKR1B1 |
|---|
| Mechanism of action | aldose reductase inhibitor |
|---|
| Indication | cardiomyopathy |
|---|
| Disease area | cardiology |
|---|
All known targets
Mechanisms of action (all sources)
- AKR1B1 INHIBITOR
- Aldose reductase inhibitor
Cross-references
Synonyms
- Aldose reductase-in-1
- AT-001
- Aldose reductase-IN-1
- At 001
- E8I3O45DDU
- AT001
- RefChem:122669
- Caficrestat [USAN]
- XXQ
- MFCD29472264
- Aldose reductase-IN-1?
- CAFICRESTAT [INN]
- Caficrestat (USAN/INN)
- UNII-E8I3O45DDU
- SCHEMBL359604
- orb1308678
- AT 001 [WHO-DD]
- C17H10F3N5O3S
- SCHEMBL29444132
- YRGPAXAVTDMKDK-UHFFFAOYSA-N
- EX-A4257
- FEC61271
- WHO 11609
- AKOS030526447
- CS-5128
- NCGC00484072-01
- DA-60892
- HY-18967
- MS-27395
- D12390
- F85302
- T14175
Look up CAFICRESTAT in the interactive SynDRA portal →